Shares of Eli Lilly and Company (LLY) fell as much as 3% on Monday after an analyst highlighted a report of liver failure in a patient taking Foundayo, the company’s new oral weight-loss medication.
“Onus is on LLY to ensure that proper and expedient adjudication of each of such liver cases is being done commercially to avoid any confusion,” Evercore ISI analyst Umer Raffat, who first flagged the case, said in a note.
The incident, which appeared in the FDA's Adverse Event Reporting System (FAERS), involved a 56-year-old male. However, Raffat provided context that hepatic failure cases have occurred with other GLP-1 drugs. Mounjaro and Zepbound, both from Lilly, have reported 30 and 2 cases respectively, while Novo Nordisk’s Ozempic and Wegovy have seen 33 and 15 cases.
This single case has drawn investor attention due to historical concerns over liver toxicity in other oral weight-loss drug candidates. Lilly responded promptly, stating its own investigation found the case was not related to Foundayo. The company’s stock partially rebounded to trade around $934 after the initial drop.
Broader Context and Market Reaction
Several analysts characterized the market’s reaction as excessive. Wolfe analyst Alexandria Hammond called the pre-market response “overdone” and viewed the price weakness as a buying opportunity. Bernstein’s Christian Moore echoed this sentiment, arguing a significant liver toxicity issue was unlikely to have been missed in Foundayo’s extensive clinical trials, which included the 2,800-patient ACHIEVE-4 study that specifically found no hepatic safety signal at the FDA’s request.
Despite the safety concerns, Foundayo has demonstrated strong initial adoption since its launch last month, enrolling 20,000 patients. Notably, 80% of these users are new to GLP-1 therapies, suggesting the oral format is expanding the market rather than cannibalizing existing injectable treatments. The drug’s convenience—not requiring an empty stomach—gives it an edge over Novo Nordisk’s oral alternative.
The market sensitivity highlights the high stakes in the booming weight-loss drug market, where Lilly holds a dominant 60% share in the U.S. The company’s injectable drugs, Mounjaro and Zepbound, recently reported massive revenue growth of 125% and 80%, respectively.
The report’s emergence puts pressure on Lilly to manage public perception and transparently address any safety concerns, however minor. For investors, the stock's dip tests confidence in a high-flying name against the backdrop of a massive, and still growing, market opportunity. The key catalyst will be continued monitoring of adverse event data and Lilly's ability to reassure patients and physicians.
This article is for informational purposes only and does not constitute investment advice.
